06.04.2016 • News

Teknor Apex Buys Plastic-Technologie-Service

US-based Teknor Apex has acquired Plastic-Technologie-Service (PTS), a German custom compounder of thermoplastic elastomers (TPEs) and engineering thermoplastics (ETPs), for an undisclosed price. The transaction was completed on Mar. 31.

PTS, which has more than 100 employees, contributes a production plant at Steinsfeld, Germany, with a capacity of 20,000 t/y, as well as a technical support facility. A marketing office is also located nearby in Tauberzell.

The company has been making TPE and ETP compounds for Teknor Apex for the past year under a tolling agreement. The two firms have also enjoyed a 15-year relationship involving licensing agreements.

Teknor Apex already compounds TPEs in Genk, Belgium, and produces compounds at its other locations in the US, Singapore and China.

PTS has a diverse portfolio, including block copolymers based on a number of polymer chemistries, thermoplastic vulcanizates (TPVs) and polymer blends. Its ETPs include several types of polyamide as well as polybutylene terephthalate (PBT), PC and PC/ABS blends.

Proprietary specialties include a hard/soft technology for over-molding TPEs onto polar ETP substrates, such as nylon and acetal, and producing a durable bond. Another specialty is radiation-crosslinked grades of ETPs and TPEs.

Jonathan Fain, chairman and CEO of Teknor Apex, said the acquisition is a natural fit with the company’s strategic vision to support the market with a global footprint and local presence.

PTS, as a subsidiary of Teknor Apex, will continue to supply products under its existing brands and its managing director, Uwe Stenglin, will remain in his role.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.